This information was published on 2026-01-16T09:16:09 for IP Right Acceptance Published.
| Field | Value |
| (210) | 2613378 (IR 1892893) |
| (220) |
05 Nov 2025
|
| (300) |
US, 06 May 2025, 99172007
|
| (511) (510) |
Class 5
Biological preparations for medical use in the treatment of genetic diseases and disorders, and muscle disorders, namely, Duchenne muscular dystrophy; pharmaceutical preparations, namely, recombinant adeno-associated viral (rAAV) vectors for use in gene therapy; pharmaceutical preparations for the treatment of genetic diseases and disorders, and muscle disorders, namely, Duchenne muscular dystrophy; clinical medical reagents for use in gene therapy; therapeutic pharmaceutical compositions that include recombinant adeno-associated viral (rAAV) vectors to provide a platform for specific expression of biologics with therapeutic effect in gene therapy; pharmaceutical preparations containing adeno-associated viral (AAV) vectors and nucleic acids for a system delivering genes to biological cells for use in the treatment of genetic diseases and disorders, namely, Duchenne muscular dystrophy; gene therapy preparation for medical use containing genetic materials for sustained protein expression, namely, microdystrophin expression. |
| (540) | NAVGENVYS |
| (550) | Word |
| (730) |
REGENXBIO Inc.
|
Find out more about publications on the About page.